Proteome Sciences PLC (GB:PRM)
LSE:PRM
PRM Stock Chart & Stats
2.85 p
-0.10 p(-2.84%)
At close: 4:00 PM EST
2.85 p
-0.10 p(-2.84%)
Day’s Range― - ―
52-Week Range1.30 p - 4.50 p
Previous CloseN/A
Volume41.42K
Average Volume (3M)476.64K
Market Cap
£5.63M
Enterprise Value19.35M
Total Cash (Recent Filing)£263.00K
Total Debt (Recent Filing)£15.39M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding350,724,900
10 Day Avg. Volume209,671
30 Day Avg. Volume476,642
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-1.54
Price to Sales (P/S)2.05
P/FCF Ratio-9.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Proteomics ExpertiseProteome Sciences' core capability in mass spectrometry and biomarker discovery is a durable technical moat. High scientific complexity and specialized instrumentation create barriers to entry, supporting long-term client relationships with pharma/biotech and enabling premium, hard-to-replicate service offerings.
Fee-for-Service Contract Research ModelA fee-for-service contract research model produces recurring project-based revenues and multi-client exposure. Long-term partnerships and repeat studies with pharma, biotech, and academia can provide stable revenue streams and predictable project pipelines, supporting multi-month operational planning.
Exposure To Personalized Medicine DemandOperating squarely in proteomics and diagnostics ties the business to secular growth in personalized medicine and biomarker-driven drug development. This structural industry tailwind increases the addressable market and the likelihood of sustained demand for specialized analytical services over the medium term.
Bears Say
Negative Equity / Solvency RiskNegative stockholders' equity is a material solvency concern that limits financial flexibility. It raises the likelihood of higher funding costs or equity dilution, constrains investment in R&D and capacity expansion, and can impair long-term competitiveness if not remedied through sustained profitability or recapitalization.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicate structural cash-generation problems. Without positive OCF, the company must rely on external financing for operations and capex, increasing execution risk and potentially limiting the ability to sustain service delivery, invest in equipment, or hire technical staff.
Declining Revenue And Ongoing LossesA drop in revenue alongside negative EBIT and net margins suggests the business isn't scaling fixed-cost operations effectively. Continued top-line decline and losses erode runway, weaken negotiating power with clients, and reduce resources for R&D and commercialization, posing sustained operational risk.
Proteome Sciences News
PRM FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 1.30 p and its highest was 4.50 p in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is £5.63M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Aug 26, 2026 which is in 148 days.
How were Proteome Sciences PLC’s earnings last quarter?
Currently, no data Available
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in GB:PRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.